Pregabalin (PGB) Rapid Test

Pregabalin is a prescription medicine used to treat specific nerve-related pain conditions and certain seizure disorders. It may be used for neuropathic pain related to diabetes, postherpetic neuralgia, nerve pain after spinal cord injury, fibromyalgia, and as add-on therapy for selected seizure types. From a screening point of view, pregabalin is important because it is a legitimate medicine but may also be misused.

• The PGB rapid test is important for professional drug screening programs because pregabalin may be prescribed legally, used outside prescription guidance, or monitored in rehabilitation and compliance settings.
• The LARKSOIS Pharma Pregabalin PGB Rapid Test may be used in drug of abuse screening programs, rehabilitation centers, clinical toxicology screening, hospitals, diagnostic laboratories, workplace or compliance screening where permitted, prescription monitoring support, and international diagnostic distribution.
• The PGB urine rapid test helps professional users screen urine specimens quickly and decide whether further confirmation is needed.

The Pregabalin (PGB) Rapid Test by LARKSOIS Pharma may be used in professional diagnostic and institutional screening environments.

Applications

• Drug of abuse screening programs
• Rehabilitation and de-addiction centers
• Clinical toxicology screening
• Hospitals and diagnostic laboratories
• Workplace or compliance screening where permitted
• Prescription monitoring support
• International diagnostic distribution
• Laboratory and institutional drug monitoring workflows

• The Pregabalin PGB Rapid Test generally works through a rapid immunoassay format. A urine specimen is collected in a clean container, the test is performed according to the product insert, and the visual result is read within the specified time window.
• The 300 ng/mL cut-off means the test is designed to screen for pregabalin at or above the stated threshold.
• A negative result means pregabalin was not detected above the cut-off at the time of testing. A non-negative result means pregabalin may be present and should be confirmed when required.
• Like other rapid drug screening products, the PGB rapid test kit is intended for preliminary screening only. Confirmatory testing should be used when results have legal, occupational, or clinical consequences.

The Pregabalin (PGB) Rapid Test uses a rapid urine screening method for qualitative detection of pregabalin. It is designed to provide a preliminary screening result at the stated 300 ng/mL cut-off.

Benefits

• Urine-based pregabalin screening
• 300 ng/mL cut-off for professional screening needs
• Fast qualitative drug of abuse screening
• Simple rapid test format
• Suitable for laboratories and field screening programs
• Useful for rehabilitation, clinical, compliance, and toxicology testing
• Supports international diagnostic supply
• Helps identify samples that may require confirmatory testing

The Pregabalin (PGB) Rapid Test is designed for urine specimens. Urine is widely used in drug screening because it is practical, non-invasive, and suitable for professional toxicology screening workflows.

Guidance

• Use urine specimens only
• Use a clean urine specimen container
• Follow the product insert exactly
• Read results within the stated time window
• Do not reuse the test device
• Record test details correctly
• Treat all urine samples as potentially biohazardous
• Confirm non-negative or disputed results through laboratory testing

Note

A rapid screening result should be considered preliminary unless confirmed by a validated laboratory method where required.

The Pregabalin (PGB) Rapid Test by LARKSOIS Pharma has a stated cut-off of 300 ng/mL. This means the test is designed to screen urine specimens for pregabalin at or above the validated threshold. LARKSOIS Pharma should mention the exact performance details according to the final product insert, technical file, and regulatory documentation.

• Pregabalin may cause dizziness, drowsiness, blurred vision, dry mouth, weight gain, swelling, and difficulty concentrating.
• Serious reactions may include allergic swelling, breathing problems, chest pain, vision changes, or severe drowsiness.
• Because of these safety concerns and misuse potential, the PGB urine rapid test can support responsible screening in professional environments.

The Pregabalin PGB Rapid Test is intended for preliminary screening only. It cannot determine exact dose, timing, impairment, medical need, or misuse. A non-negative result should be reviewed with medical history, prescription information, testing policy, and confirmatory laboratory results when required.

Instructions

• Pregabalin level may be below the cut-off
• Testing may occur outside the detection window
• Diluted or adulterated urine specimen may affect results
• Incorrect sample handling may affect performance
• Reading the result too early or too late may affect interpretation
• Cross-reactivity may occur depending on assay design
• Always follow the LARKSOIS Pharma product insert for exact procedure, storage, timing, limitations, and interpretation

Instructions

• Urine-based pregabalin screening
• 300 ng/mL cut-off for professional screening needs
• Fast qualitative drug of abuse screening
• Simple rapid test format
• Suitable for laboratories and field screening programs
• Useful for rehabilitation, clinical, compliance, and toxicology testing
• Supports international diagnostic supply
• Helps identify samples that may require confirmatory testing

Note

The Pregabalin PGB Rapid Test by LARKSOIS Pharma is developed for professional users who need a practical, reliable, and internationally suitable pregabalin screening solution.

Steps

• Bring the test device and urine specimen to the recommended testing condition
• Open the sealed pouch only when ready to test
• Collect urine using a clean sample collection procedure
• Apply the urine specimen according to the product insert
• Wait for the test reaction to complete within the instructed time
• Read the result within the approved interpretation window
• Dispose of used materials according to laboratory safety rules

Note

The exact procedure must follow the official LARKSOIS Pharma product insert supplied with the Pregabalin (PGB) Rapid Test.

Positive

A positive or non-negative result suggests that pregabalin may be present in the urine specimen at or above the stated cut-off. Positive results are preliminary and should be confirmed using a recognized laboratory method where required.

Negative

A negative result suggests that pregabalin was not detected or was below the cut-off at the time of testing. A negative result does not always rule out exposure if sample quality, collection timing, or the detection window affects the result.

Invalid

If the valid control indicator does not appear, the test is invalid. The test should be repeated with a new device and fresh urine specimen according to the product insert.

Instructions

• Store according to the product label and package insert
• Keep the test sealed until use
• Protect it from moisture and direct sunlight
• Avoid using expired or damaged devices
• Use a clean urine specimen container
• Read results within the stated time window
• Do not reuse the test device

Instructions

• For professional screening use only
• Use urine specimen only as directed
• Do not reuse the test device
• Follow the product insert carefully
• Handle all urine specimens as potentially infectious material
• Do not interpret results after the recommended reading time
• Confirm presumptive positive results with laboratory testing
• Follow applicable drug testing laws and reporting requirements

LARKSOIS Pharma provides international-quality pharmaceutical and diagnostic products for global healthcare and screening markets. The Pregabalin PGB Rapid Test is suitable for diagnostic distributors, hospitals, laboratories, rehabilitation centers, workplace testing providers, and toxicology screening programs.

Advantages

• International diagnostic product focus
• Reliable rapid testing solutions
• Suitable for laboratories and healthcare suppliers
• Distributor-friendly product format
• Supports drug of abuse screening programs
• Designed for practical urine screening workflows
• Quality-focused standards under LARKSOIS Pharma